0001127602-24-000110.txt : 20240102
0001127602-24-000110.hdr.sgml : 20240102
20240102160930
ACCESSION NUMBER: 0001127602-24-000110
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240101
FILED AS OF DATE: 20240102
DATE AS OF CHANGE: 20240102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dunlop A. Sinclair
CENTRAL INDEX KEY: 0001721108
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 24502466
MAIL ADDRESS:
STREET 1: C/O APELLIS PHARMACEUTICALS, INC.
STREET 2: 6400 WESTWIND WAY, SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-01-01
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001721108
Dunlop A. Sinclair
C/O APELLIS PHARMACEUTICALS, INC.
100 FIFTH AVENUE, 3RD FLOOR
WALTHAM
MA
02451
1
0
Common Stock
2024-01-01
4
A
0
3341
0
A
132018
D
Common Stock
192679
I
Indirect Owner (Epidarex)
Common Stock
31855
I
Indirect Owner (Masa)
Stock Option (Right to Buy)
59.86
2024-01-01
4
A
0
5748
59.86
A
2030-12-31
Common Stock
5748
5748
D
This restricted stock unit was granted on January 1, 2024. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election.
The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.
This option was granted on January 1, 2024. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant.
/s/ David Watson, attorney-in-fact for Sinclair Dunlop
2024-01-02